Rallybio GAAP EPS of -$0.22, revenue of $212M
Source: SeekingAlpha
2025-08-07 09:42:17 ET
More on Rallybio
- Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug
- Seeking Alpha’s Quant Rating on Rallybio
- Historical earnings data for Rallybio
- Financial information for Rallybio
Read the full article on Seeking Alpha
For further details see:
Rallybio GAAP EPS of -$0.22, revenue of $212M
Rallybio Corporation
NASDAQ: RLYB
RLYB Trading
-8.97% G/L:
$9.94 Last:
49,171 Volume:
$10.80 Open:
RLYB Latest News
RLYB Stock Data
$25,346,266
4,324,707
0.55%
9
N/A
Biotechnology & Life Sciences
Healthcare
US
New Haven
